AIOLOSNCT05344469
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 49 versions: 49 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 27 words
- Trial sites expanded: 141 → 146 locations
- Secondary endpoints: details revised at 22 of 49 entries
- Study description revised
- Minor Trial sites expanded: 138 → 141 locationsv48
- Minor Trial sites expanded: 129 → 138 locationsv47
- Minor Study sites: 127 to 129v46
- Minor Trial sites expanded: 119 → 127 locationsv45
- Minor Trial sites expanded: 111 → 119 locationsv44
- Notable Enrollment target: 1214 to 800
- Study sites: 108 to 111
Notable Trial status: Active, Not Recruiting to Recruitingv42 Show 9 more changesShow less
- Enrollment target: 564 to 1214
- Primary and study completion dates: Dec 31, 2026 to May 30, 2029
- Eligibility criteria expanded, about 185 words
- Primary endpoint revised
- Study sites: 90 to 108
- Interventions: glatiramer acetate (Other), interferon β1 (Other), ofatumumab (Other) to dimethyl fumarate (DMF) (Other), diroximel fumarate (DRF) (Other), glatiramer acetate (Other), interferon β1 (Other), ofatumumab (Other)…
- Secondary endpoints: 28 to 49
- Study description expanded, about 88 words
- Study title expanded, about 3 words
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 800 to confirmed 564
- Study sites: 101 to 90
- Minor Study sites: 100 to 101v40
- Minor Site details revised at 1 of 100 sitesv39
- Minor Study sites: 98 to 100v38
- Minor Study sites: 97 to 98v37
- Notable Primary and study completion dates: Oct 17, 2025 to Dec 31, 2026
- Eligibility criteria expanded, about 1 word
- Study sites: 96 to 97
- Secondary endpoints: 27 to 28
- Minor Site details revised at 1 of 96 sitesv35
- Minor Study sites: 91 to 96v34
- Minor Study sites: 89 to 91v33
- Minor Study sites: 88 to 89v32
- Minor Study sites: 86 to 88v31
- Minor Study sites: 84 to 86v30
- Minor Study sites: 82 to 84v29
- Minor Study sites: 78 to 82v28
- Minor Study sites: 69 to 78v27
- Notable Eligibility criteria expanded, about 7 words
- Study sites: 68 to 69
- Minor Study sites: 67 to 68v25
- Minor Study sites: 64 to 67v24
- Minor Study sites: 63 to 64v23
- Minor Study sites: 62 to 63v22
- Minor Study sites: 60 to 62v21
- Minor Study sites: 55 to 60v20
- Minor Study sites: 54 to 55v19
- Minor Study sites: 49 to 54v18
- Minor Study sites: 45 to 49v17
- Minor Study sites: 44 to 45v16
- Minor Study sites: 43 to 44v15
- Minor Study sites: 41 to 43v14
- Minor Study sites: 36 to 41v13
- Minor Study sites: 34 to 36v12
- Minor Study sites: 33 to 34v11
- Minor Study sites: 32 to 33v10
- Minor Study sites: 28 to 32v9
- Minor Study sites: 27 to 28v8
- Minor Study sites: 26 to 27v7
- Minor Study sites: 24 to 26v6
- Minor Study sites: 18 to 24v5
- Minor Study sites: 17 to 18v4
- Minor Study sites: 10 to 17v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 10
- Start date changed from estimate of May 2, 2022 to May 10, 2022
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Proportion of patients who continue to receive their baseline treatment
Timeframe: Month 24
Secondary (49)
Proportion of patients who continue to receive their baseline treatment
Time to event analysis for retention time on baseline treatment
Impact of first-line treatment on health economy
Fatigue Symptoms and Impact Questionnaire-RMS
Patient Health Questionnaire 8 [PHQ-8]
Show 44 moreShow less
Generalized Anxiety Disorder Scale 7 [GAD-7]
Multiple Sclerosis Impact Scale 29 v2
Quality of Life in Neurological Disorders [NeuroQoL]
MS Treatment Concerns Questionnaire [MSTCQ]
Expanded disability status scale (EDSS)
Time to onset of confirmed disability worsening (CDW)
Proportion of patients with confirmed disability worsening (CDW)
Time to onset of confirmed disability improvement (CDI)
Proportion of patients with CDI
T1 Gd-enhancing lesions per brain
Annualized T2 lesion rate
Presence of spinal cord lesions
Proportion of patients with no evidence of disease activity (NEDA3) upon discretion of the investigator.
Proportion of patients with no clinical disease activity and no discontinuation of current treatment due to AEs
Annualized relapse rate
Time to first relapse
Proportion of relapse free patients
Serum NfL levels
Proportion of patients with low or elevated sNfL levels
Association of selected effectiveness and PRO outcomes with sNfL levels
Reasons for treatment decisions
Number of patients and reasons for discontinuation of treatment
Proportion of patients who continue to receive their subsequent treatment
Reasons for and number of treatment interruptions per patient
Duration of treatment interruptions per patient
Number of patients with treatment interruptions
Proportion of drug-related adverse events (AEs)
Persistence of drug-related adverse events (AEs)
Specific safety assessment of injection related AEs
Proportion of participants discontinuing treatment due to insufficient effectiveness (lack of efficacy) or tolerability/safety reasons
Proportion of sites that share the standardized MRI report form with their radiological colleagues
Proportion of standardized MRI report forms and conventional radiologists' reports
Effect of standardized MRI report form on completeness of lesion documentation
Physician's view on added value of standardized MRI report form over conventional radiologists' reports
Proportion of patients and physicians that intend to view and use PRO and sNfL results to support patient-physician dialogue
Proportion of patients that access their PRO and sNfL result visualizations at least once every 6 months
Perceived value of PRO and sNfL result visualizations from the perspective of both patient and treating physician on patient-physician dialogue and shared decision making
Age of male and female participants
Number of previous MS relapses of male and female participants
Serum NfL levels of male and female patients
Proportion of male and female patients who continue to receive their baseline treatment
Annualized relapse rate of male and female patients
Reasons for treatment decisions of male and female patients
Quality of Life in Neurological Disorders [NeuroQoL] of male and female patients
Arms and interventions
Ofatumumab
Patients treated with ofatumumab
Standard of Care (SoC)
Patients treated with either interferon β1 (IFN-β1), glatiramer acetate (GA), teriflunomide, dimethyl fumarate (DMF) or diroximel fumarate (DRF)
Other: ofatumumab, glatiramer acetate, interferon β1, teriflunomide, dimethyl fumarate (DMF), diroximel fumarate (DRF)
Sites
146 sites in 1 country